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August 16, 2005:730–42isks of this technique. This is the classic scientific paradigm: if the
urrent theory does not fit the data, then revise the theory; do not
iscount reproducible data. The strength and consistency of the
bservations are compelling enough to give this randomized
linical trial a chance.
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atheter Ablation After Mitral Replacement
ang et al. (1) report their experience of transcatheter ablation of
trial fibrillation (AF) in patients with mitral valve prostheses
MVP). The investigators claim that patients in both groups were
t the extreme end of the spectrum of atrial disease. However,
ore patients (a total of 14) had paroxysmal AF than did those
ith chronic AF; this does not necessarily constitute the extreme
nd of the disease. Did the researchers note any significant
ifferences in the incidences of AF recurrences between those who
ad paroxysmal and those who had chronic AF?
Lang et al. (1) conclude that the outcomes are similar to those
f standard patients undergoing catheter ablation, yet the 73%
75% in controls) sinus conversion rate falls far short of the results
chieved by current surgical techniques. The need for subsequent
ntervention for atrial tachycardia (AT) and recurrent AF was
retty high. Given that AF circuits are unstable, what was the
ncidence of peri-procedural AF in these patients?
Moreover, the lines of ablation varied within as well as between
he groups. Was this variation based on the findings of mapping?
t would have been interesting to know what the findings of the
apping were in terms of the sites of the triggers. Given that the
ines of ablation were different in these patients, how did the
nvestigators compare the incidences of AF recurrence and AT
etween the two groups?
Although most studies have concentrated on the conversion to
inus rhythm, AT is emerging as a troublesome complication of
ost forms of intervention. It is significant that the incidence of
T was 29% in the MVP group, particularly considering that all
atients in this group had specific lines of ablation to preclude AT!
Surgical scarring as a cause of AT in these patients is not a
enable explanation as none of them had preablation AT. It is
ore likely to be a consequence of the inability to create an
dequate block at the mitral isthmus owing to the fear of damaging
he prosthesis. It is well recognized that the creation of incomplete
ines of block will facilitate macro-reentrant arrhythmias. This rate
f sinus conversion and prevention of AT is then contingent on
ur ability to close the mitral isthmus adequately within these patients, without damaging the prosthesis. We clearly need to
efine the ablation technique to address this issue.
None of these patients had a preprocedural diagnosis of AT,
uggesting that AT was a consequence of the ablation. Are we then
erely replacing one arrhythmia with another? Evidently we need
o address this issue.
Notwithstanding these limitations, Lang et al. (1) are to be
ongratulated for achieving good results in a unique group of
atients who are difficult to treat. Ostensibly, the number of such
atients will be reduced in the future, as most of these patients will
ow have AF ablation, concomitant to mitral repair or replacement.
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EPLY
e are thankful for the comments made by Dr. Shanmugam as we
an further emphasize major points already addressed in the
ethods and Discussion sections of our original study (1). Most of
ll, our goal was to establish for the first time the safety and
easibility of transcatheter ablation of atrial fibrillation (AF) in a
ery challenging group of patients with mitral valve prosthesis
MVP). We even performed a live satellite broadcast of such a
rocedure at the last Boston Atrial Fibrillation Symposium on
anuary 14, 2005, in a patient with MVP and chronic AF, where
e were able to cardiovert and maintain her into sinus rhythm
rom the end of the ablation until now.
In our study (1), patients with MVP had both paroxysmal AF
14 patients) and chronic AF (13 patients). Extreme end of the
trial disease was not merely based on the type of AF but on the
act that AF was highly symptomatic and refractory to at least two
ntiarrhythmic drugs in patients with very enlarged left atrium (55
m). Also, the 73% (75% in the control group) maintenance rate
f sinus rhythm was achieved by percutaneous transcatheter
blation in this selected group of patients. It is not rare to see AF
ccurrence within the first month following the ablation procedure
wing to tissue inflammation, and this does not generally influence
he outcomes. Some patients did not have additional lines done in
he left atrium as we were in the process of assessing the benefit of
hese lines, as already mentioned in the original report (1). This
as not due to variation in anatomic mapping. Furthermore, 81%
f patients in both groups had additional lines performed along the
itral isthmus and in the posterior wall; 12% of the MVP group
vs. 13% of the control group) had only the mitral isthmus line
one (again, as we were investigating the benefit of additional
ines; data now published [2]), allowing us to compare outcomes in
oth groups. Postablation left atrial tachycardia occurred in six
atients of the MVP group (one in the control group), probably to
